▼ 1.44%
prev close
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.
Congressional Trades
1
All tracked trades
Members Trading
1
Unique members
Net Activity
-1
0 buys · 1 sells
Members Who Traded This Stock
1 trade events
| Date | Member | Stock | Type | Amount | Filed | Signal |
|---|---|---|---|---|---|---|
| 2023-03-31 | GRFSGrifols, S.A. - American Depositary Shares | Sell | $1,001 - $15,000 | 1282d ago | — |
2023-03-31
Daniel Goldman
GRFS
Amount
$1,001 - $15,000
Filed
1282d ago
Recent News
Powered by Polygon.io
European Human Biospecimen Market Forecasts Growth from $881.8M (2025) to $1.94B by 2035, Profiling Grifols, Logical Biological & Europa Biosite
Intravenous Immunoglobulin Market Size Worth USD 30.83 Billion by 2035, Growing at 7.49% CAGR – SNS Insider
[Latest] Global Botulinum Toxin in Urology Market Size/Share Worth USD 1.98 Billion by 2035 at a 6.08% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
Hepatic Encephalopathy Market Set for Growth at a 1.2% CAGR Through 2036, Driven by Emerging Therapies and Rising Disease Burden | DelveInsight
Ban Grifols and return plasma collection to Canadian Blood Services and Héma-Québec, say health care advocates
Trade Timeline
Congressional activity, newest first
Daniel Goldman
2023-03-31 · Sale
$1,001 - $15,000